Friday, October 15, 2021

Merck lands option on Symvivo’s oral vaccine delivery platform

Merck has secured an exclusive option to license Symvivo’s bacTRL platform for use in oral vaccine delivery. The research collaboration positions Merck to evaluate a technology that uses engineered bacteria to deliver genetic material.

Symvivo develops oral vaccines by genetically modifying probiotic bacteria. Upon administration, the bacteria shepherd their genetic payloads through the upper gastrointestinal tract and then colonize the large intestine. Bacteria in the colony bind to intestinal epithelial cells, replicate and deliver DNA that encodes for a molecule linked to the targeted pathogen.

Merck has secured an exclusive option to license the technology for the oral delivery of vaccines through a research collaboration with Symvivo, thereby becoming the second big company in quick succession to show an interest in the technology. Johnson & Johnson formed a research collaboration to assess the use of bacTRL in therapeutics late last year.  

Symvivo, like other developers of novel technologies applicable to vaccines, has advanced work on its platform during the pandemic. Late last year, Symvivo dosed the first participant in a clinical trial of its bacTRL-Spike COVID-19 vaccine, marking the first time a human had received an orally delivered bacTRL.

The COVID-19 clinical trial is assessing three doses of bacTRL-Spike. Participants will receive either 1 billion, 3 billion or 10 billion colony-forming-units of live Bifidobacterium longum. Symvivo has engineered the bacteria to deliver plasmids. The plasmids contain DNA that encodes for the SARS-CoV-2 spike protein targeted by all COVID-19 vaccines.  

If effective, bacTRL-Spike will have two key advantages over first-generation COVID-19 vaccines. Firstly, the vaccine is delivered orally. Secondly, the vaccine is stored at room temperature. Those features could simplify the logistics of mass-vaccination campaigns and eliminate dislike of needles as a potential barrier to uptake. 

While COVID-19 has tipped interest in bacTRL toward its infectious disease applications, Symvivo also sees scope to use the platform to develop oncology, cardiovascular and genetic disease products. 

Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...